Sorry you're right, I had the terminology wrong. It's abandoned, not orphaned, and the specific program is FDA NCIE.
IIRC this program grants advertising exclusivity (weaker than patent exclusivity) as a carrot to give companies "IP protection-lite" in exchange for re-testing old drugs under the FDA phase flow.
Legally, it was above board, and financially, it was sensible regulatory arbitrage. Morally, though, it was reprehensible.